Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Terminated × Neurofibroma, Plexiform × 1 year × Clear all

Status

Recruiting 9 Active not recruiting 7 Not yet recruiting 3 Terminated 1 Enrolling by invitation 1 Completed 1

Sponsor Class

Study Type

Observational 1

Sponsor

Cancer Type

Conditions

Carcinoma, Non-Small-Cell Lung 115 Breast Neoplasms 101 Neoplasms 82 Neoplasm Metastasis 76 Leukemia, Myeloid, Acute 71 Melanoma 64 Colorectal Neoplasms 64 Prostatic Neoplasms 63 Ovarian Neoplasms 50 Lung Neoplasms 50 Multiple Myeloma 45 Pancreatic Neoplasms 41 Squamous Cell Carcinoma of Head and Neck 40 Recurrence 40 Triple Negative Breast Neoplasms 37 Carcinoma, Renal Cell 34 Carcinoma, Hepatocellular 33 Myelodysplastic Syndromes 32 Lymphoma, Non-Hodgkin 32 Brain Neoplasms 32 Endometrial Neoplasms 30 Lymphoma 28 Uterine Cervical Neoplasms 27 Stomach Neoplasms 27 Leukemia 27 Glioblastoma 27 Cholangiocarcinoma 27 Head and Neck Neoplasms 24 Leukemia, Lymphocytic, Chronic, B-Cell 23 Precursor Cell Lymphoblastic Leukemia-Lymphoma 22

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05683678 2025-04-04

US Selumetinib Registry

Alexion Pharmaceuticals, Inc.

Neurofibromatosis 1, Neurofibroma, Plexiform

Data powered by HemOnc (CC BY 4.0) Colophon ⚡